Hospital

With this action, Thrombate III has become the first and only antithrombin concentrate approved for adult and pediatric patients with hereditary antithrombin deficiency (hATd).

Plozasiran gains FDA approval to significantly lower triglycerides in adults with Familial Chylomicronemia Syndrome, enhancing heart health management.

Epcoritamab-bysp demonstrated impressive response rates and improved progression-free survival.

Pharmacy team members who participated in a gamified virtual escape room reported higher levels of readiness and confidence to respond to emergency-scenario disaster events.

Neladalkib offers durable responses and reduced side effects in TKI-pretreated patients.

Mount Sinai's study uncovers how ciltacabtagene autoleucel enhances long-term remission in multiple myeloma by leveraging the patient's immune response.

Patients with non–small cell lung cancer (NSCLC) had an objective response rate of about 77%.

SHR-A1811 is a novel HER2-targeting ADC comprised of trastuzumab linked to a topoisomerase I inhibitor payload via a cleavable linker.

New research shows that an increased consumption of ultraprocessed foods significantly raises prediabetes risk in young adults, highlighting urgent dietary intervention needs.

New research reveals similar severe outcomes for adults hospitalized with hMPV and RSV, emphasizing the need for awareness of both infections.

Ziftomenib gains FDA approval as a targeted treatment for relapsed acute myeloid leukemia with NPM1 mutations, offering new hope for patients.

Nazia Somani Babul, PharmD, BCACP, often serves as a primary or coinvestigator and collaborates with pharmacists, students, and residents.

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

Only Humans Can Ensure AI Is Ethical and Unbiased

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.

Semaglutide shows significant weight loss and reduces obesity-related health risks, offering a promising solution for effective weight management.

The new year can present challenges to health-system pharmacy.

Pharmacists’ expertise is vital to AI’s safe integration into medication management. A growing array of resources and training supports pharmacists’ engagement with this new technology.

Inclisiran significantly enhances LDL-C goal attainment in post-acute coronary syndrome patients, improving lipid management outcomes.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

Consistent use of continuous glucose monitoring (CGM) significantly improves glycemic control in adults with type 2 diabetes (T2D).

SHR-A1811 shows significant antitumor activity in early-stage HER2+ breast cancer, both alone and with pyrotinib, promising improved treatment outcomes.

Maternal type 1 diabetes may influence children's DNA, potentially reducing their risk of developing islet autoimmunity.

New findings suggest omitting radiation therapy in postmastectomy breast cancer treatment enhances survival, emphasizing the role of systemic therapies.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.